Breaking News: Dupixent (Dupilumab) Receives CHMP Recommendation for Expanded EU Approval to Treat Severe Atopic Dermatitis in Children as Young as Six Months Old
Dupixent® (dupilumab) Recommended for Expanded EU Approval by the CHMP Introduction Exciting news in the world of dermatology as Dupixent is recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitis. If approved, Dupixent would be the first and only targeted medicine in the…